• Service
  • Resources
    • Webinars
    • Upcoming Events
    • Documents Download
    • FAQ
    • NMPA Approval Report
  • News
  • CER
  • About
Subscribe

Our Services

Strategy Consulting

  • Market Entry Strategy
  • Regulatory Strategy
  • Clinical Strategy
  • China Localization Strategy
  • Hainan Urgent Use Pathway
  • Innovation Pathway
  • Fast Track Pathway
  • Digital Health Consulting

Registration Affairs

  • Pre-market Registration
  • Modification Registration
  • Renewal Registration
  • Request for Classification
  • Legal Agent Representation
  • NMPA Expert Panel Meeting
  • NMPA Supplemental Notice

Quality Assurance

  • Postmarket Surveillance Compliance (IFU, Label, GSP)
  • Adverse Event Reporting
  • Recall Handling
  • Periodic Risk Evaluation Report
  • Annual QMS Self-Inspection Report
  • NMPA Inspections & Mock-Audit
  • QMS Establishment/Audit/Remediation
  • QA Gap Analysis
  • Factory Audit
  • Unique Device Identifier

Device Testing

  • China Local Type Testing
  • Device Modification Compliance Testing
  • Biocompatibility Testing
  • EMC Testing

Clinical Research Organization (CRO)

  • Clinical Trials/Research
  • Real-World Study
  • China CER & MDR CER
  • Clinical Evaluation Feasibility Assessment

Customized Training

  • China Regulatory Training
  • China QMS Training
  • China GCP Training
  • China Localization Training
  • Periodic Regulatory Updates Training

Other Services

  • Translation
  • Patent & Trademark
  • Distributor Evaluation & Audit
  • KOL Interview/Consultation
  • Investment
  • Global regulatory services
  • Service
  • Resources
    • Resources
    • Webinars
    • Upcoming Events
    • Documents Download
    • FAQ
    • NMPA Approval Report
  • News
  • About
  • CER
  • Subscribe
  • CN
  • US
  • Home
  • FAQ
  • IVD

FAQ


  • FAQ
  • Active Device
  • Non-active Device
  • IVD
  • HGRAC
  • Clinical Evaluation
  • Common FAQ
  • What Factors Should Be Considered In The Coverage Of Gene Mutation Sites For CDx?

    For the gene mutation detection reagent of tumor companion diagnosis (CDx), if the gene is known to have multiple mutation sites for the same companion diagnosis purpose (such as the same companion drug), the coverage of mutation sites shall be fully considered in combination with product risk benefit analysis in subsequent product design, and the detection range of sites shall not be arbitrarily reduced for the convenience of product evaluation. For example, when KRAS gene mutation is used for tumor companion diagnosis, because it is a negative companion diagnostic gene detection and related to adverse drug reactions, insufficient coverage of mutation sites may increase the risk of patients. 

    READ MORE >

  • What Tests Are Required To Add Sterilization Methods To The Registration Of Orthopedic And Oral Implants?

    To increase the sterilization method by changing the registration of permission items, it is necessary to submit sterilization verification data and carry out sterility performance test.

    In case of any other performance changes caused by the addition of sterilization methods, the test shall be conducted. For example, if the sterilization method of ethylene oxide is added, the sterility test item and residual amount of ethylene oxide shall be added.

    READ MORE >

  • What Should Be Considered In The Heat Treatment Process Of Additive Manufacturing—selective Laser Melting Metallic Materials For Removable Restorations?

    It is necessary to clarify method and parameters of heat treatment of the product, evaluating and verifying the suitability of the heat treatment method. The basis for determining the heat treatment parameters (including heating time, holding temperature, holding time, etc.) and the acceptability criteria of the results after heat treatment also need to be clarified.

    READ MORE >

  • What Certification Tests Are Required For The Monitor Products? Whether Test Results Already Available In Country Of Origin Can Be Used?

    At present, it is necessary to conduct performance parameter test, electromagnetic compatibility test (YY 0505-2012/IEC 60601-1-2:2004), electrical safety general standard test (GB 9706.1-2007/IEC 60601-1:1988 + A1 + A2, YY 0709-2009/IEC 60601-1-8:2003) and all the applicable standards of included monitoring functions, such as pulse function (YY 0784-2010/ISO 9919:2005), blood pressure function (YY 0667-2008/IEC 60601-2-30:1999), ECG monitoring function (GB 9706.25-2005/IEC 60601-2-27:1994), etc.
    From May 1, 2023, China will implement the new version of GB 9706.1 standard equivalent to IEC 60601-1:2012 and the corresponding parallel standard and special standard, at which time the test will be conducted according to the new version of the standard. Currently only the test report of IEC 60601-1: 1988 + A1 + A2 can be used directly to avoid some test items. The corresponding policies for the implementation of the new standard in 2023 have not been clarified yet.

    READ MORE >

  • The Blood Oxygen Module Used In Combination With Ventilators Shall Be Clinically Evaluated Through Laboratory Human Study. If The Product Is Not Marketed In China, Whether The Racial Difference (difference In Skin Color Evaluation) Shall Be Considered In This Evaluation?

    The ethnic differences should be considered and the data of Chinese or Asian Americans should be included.

    Recommendations based on clinical evaluation of blood oxygen: The manufacturer is advised to consider the age of patients. Different ages should be included as widely as possible, covering at least 18 to 45 years old. The problem of skin melanin precipitation should be considered in this clinical study. Subjects with different degrees of melanin precipitation (or dark skin) should be included, involving at least two subjects with melanin precipitation or at least 15% of subjects with melanin precipitation (whichever is larger).

    READ MORE >

  • How Does NMPA Supervise The Sleep Respiratory Monitoring APP Installed On The Patient’s Mobile Phone?

    How to supervise depends on the specific function and purpose of the APP. If the APP can only record and display data without the function of data processing and calculation, and its displayed data is not used for diagnosis or treatment, the APP will be classified as non-medical devices and NMPA will not supervise it.

    If the data of APP is used to assist diagnosis and treatment, and does not involve artificial intelligence technology and big data technology based on deep learning, it shall be supervised according to class II medical devices, with classification code of 21-03.

    READ MORE >

  • How To Conduct Laboratory Comparison For Predicates Without Authorization, And Whether The Reviewers Approve The Laboratory Comparison Data?

    Laboratory comparison data for unauthorized predicates can be included as part of the CER. The success of CER pathway also depends on the adequacy of other data, such as previous clinical research data, literature data, etc.

    READ MORE >

  • How To Conduct Clinical Trials Of Ventilator Integrated Cardiopulmonary Impedance Monitoring Module?

    This module is not recommended for registration with the ventilator.
    In clinical practice, the cardiopulmonary impedance indicator can be used as a reference to adjust the parameters of the ventilator. When the data reaches the adjustment indicator, the physician judges whether it is necessary to make adjustment and records the subsequent patient-related data, so as to evaluate whether the parameter indicator have positive adjustment, negative adjustment or no impact on the main effectiveness evaluation indicators.

    READ MORE >

  • What’s The Registration Unit Rule Under Chinese Regulation For Ventilators?

    A ventilator is a pulmonary ventilation device used to automatically increase or provide ventilation to a patient’s lungs. According to the Guidelines for the Classification of Registration Units of Medical Devices, active medical devices with different technical principles should be classified into different registration units.

    According to the state of the art, critical-care ventilators, home-care ventilators, ventilators for first aid and transport, high frequency jet ventilators and high frequency oscillation ventilators with different technical principles should be classified as different registration units. Critical-care ventilators with different technical principles, such as electronically controlled pneumatic ventilators and electrically powered ventilators, should be classified as different registration units.

    Ventilators with same technical principles but different product design structures (such as ventilators with different gas circuit designs) should be classified as different registration units. Passive consumables (such as breathing tube, tracheal cannula, mask, etc.) used in combination with the ventilator should be classified as different registration units.

    READ MORE >

  • When Conducting EMC Test For Ultrasonic Soft Tissue Cutting And Hemostatic Equipment, Is It Possible To Select A Type Of Cutter Head As A Typical Model?

    Ordinary ultrasonic cutter head (excluding transducer) only transmits sound energy, not electric energy, which theoretically has no effect on EMC performance. In order to identify the functions of disposable use and collect the working parameters of some ultrasonic cutter heads, there is a chip in the cutter head, which needs power supply and may affect the EMC performance. For the ultrasonic cutter head without chip and without transmitting conductive signal and electric energy, one type of cutter head can be selected for detection.

    READ MORE >

  • To Evaluate The Virus Inactivation Effect, Whether The Animal-based Medical Devices Must Be Subject To Laboratory Validation Of Virus Inactivation Process?

    According to Guidelines for Technical Review of Animal-based Medical Device Registration (2017 Revision), to apply for the registration of animal derived medical devices, the description of the process of inactivating and removing viruses and / or infectious factors in the production process and the effectiveness verification data or relevant materials shall be provided.

    The efficacy of virus inactivation can be validated through laboratory validation or from suppliers of animal-derived materials, or evaluated through literature or historical data. If the validation data submitted are not based on the data obtained from the validation of the declared product itself, an analysis and demonstration of its applicability shall be conducted

    READ MORE >

  • The Product Is Made Of Material Acceptable For Clinical Use In Accordance With Appendix B Of YY 0341.1. Whether Biological Dossiers Can Be Submitted In The Way Of Biological Exemption When Submitting Registration Dossiers?

    The biological evaluation can’t be exempted. The equivalence comparison can be used to prove that the product under application has the same biocompatibility with the marketed product, so as to determine the reduction or exemption of biological test for the product under application.

    For materials conforming to Appendix B of YY 0341.1, equivalence comparison is still required, such as demonstrating whether new biological risks are introduced in the production process and whether the production processes (processing process, sterilization process, packaging, etc.) are the same.

    Since the production process may also introduce new harmful substances (residues such as sterilizers, processing AIDS and demoulding agents), if it is evaluated that the production process does not introduce new biological risks, it can be considered to be exempted from biological tests.

    READ MORE >

« Prev...246...2324252627...Next »
Twitter Linkedin
United States
Email: info@bradyknowsmedical.com
Phone: +86 18600392020
China
Beijing Office: Room 1501-1502, East Ocean Centre, No. 24 A, Jianguomenwai Avenue, Chaoyang District, Beijing, China
Shanghai Office: Lingang New Zone, China (Shanghai) Pilot Free Trade Zone
Hainan Office: Boao Lecheng pilot zone of international medical tourism, Qionghai City, Hainan Province
Email: info@bradyknowsmedical.com
Phone: +86 18600392020 +86 10 65155991

©2025 Bradynuoen Beijing PharmTech Co Ltd All Rights Reserved.

京ICP备15042665号-7